12:00 AM
May 10, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Flocor: Phase III trial update

CytRx Corp. (CYTR), Atlanta, Ga.
Product: Flocor
Business: Hematology
Therapeutic category: Cell adhesion
Target: Red blood cells

Read the full 68 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >